Swiss - Delayed Quote CHF

Lonza Group AG (LONN.SW)

524.20

-3.60

(-0.68%)

As of 12:45 PM GMT+2. Market Open.

Lonza Group Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Lonza Group ( VTX:LONN ) Full Year 2023 Results Key Financial Results Revenue: CHF6.72b (up 7.9% from FY 2022). Net...

Simply Wall St. 24 days ago

LZAGY
Lonza Group AG's (VTX:LONN) largest shareholders are individual investors with 56% ownership, institutions own 44%

Key Insights The considerable ownership by individual investors in Lonza Group indicates that they collectively have a...

Simply Wall St. 25 days ago

LZAGY
Health Care Roundup: Market Talk

Find insight on Figs, Siegfried Holding and more in the latest Market Talks covering the Health Care sector.

The Wall Street Journal 26 days ago

LZAGF

LZAGY

SGFEF
Lonza Taps Siegfried Holding’s Wolfgang Wienand as Next CEO

Lonza has appointed Wolfgang Wienand, currently chief executive at peer Siegfried Holding, as its next CEO.

The Wall Street Journal 27 days ago

LZAGF

LZAGY

SGFEF
15 Biggest Swiss Companies

In this article, we will discuss the 15 biggest Swiss companies. If you want to skip our analysis, you can proceed to the section highlighting the 5 Biggest Swiss Companies. Economy of Switzerland According to a report by the Federal Council of Switzerland, the Swiss GDP growth is projected to remain sluggish at 1.1% in […]

Insider Monkey 30 days ago

NSRGF

ROG.SW
+0.90%
LZAGY
U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies

A proposed bill in Congress targets Chinese biotech businesses that play an important role in developing drugs.

The Wall Street Journal last month

MEDP

IOVA

LLY
UPDATE 2-Luxury stocks pressure European equities ahead of Fed verdict

European shares were flat on Wednesday, pressured by a sell-off in luxury stocks and in the absence of big bets by investors ahead of a crucial Federal Reserve meeting later in the day. The pan-European STOXX 600 index ended largely unchanged at 505.34 points, with the personal and household goods index housing luxury stocks, down 1.3% and leading declines.

Reuters last month

LZAGY

JMPLF

PPRUY
UPDATE 3-Lonza to buy large biologics site from Roche in US for $1.2 bln

Swiss contract drug manufacturer Lonza said on Wednesday it would buy one of the world's largest manufacturing sites for biologic drugs in California from drugmaker Roche for $1.2 billion. Lonza plans to spend another 500 million Swiss francs ($562.3 million) to upgrade the facility in Vacaville, which makes monoclonal antibodies from genetically modified living cells, to produce a new generation of drugs, the company said in a statement. Roche unveiled plans to sell the site in May last year, saying it no longer needs the very large antibody volumes the plant provides, as it plans to focus on drugs targeting smaller patient populations and a range of biotechnology methods beyond monoclonal antibodies.

Reuters last month

LZAGY

ROG.SW
+0.90%
Lonza to buy large biologics site from Roche in US for $1.2 billion

(Reuters) -Swiss contract drug manufacturer Lonza said on Wednesday it would buy one of the world's largest manufacturing sites for biologic drugs in California from drugmaker Roche for $1.2 billion. Lonza plans to spend another 500 million Swiss francs ($562.3 million) to upgrade the facility in Vacaville, which makes monoclonal antibodies from genetically modified living cells, to produce a new generation of drugs, the company said in a statement. Roche unveiled plans to sell the site in May last year, saying it no longer needs the very large antibody volumes the plant provides, as it plans to focus on drugs targeting smaller patient populations and a range of biotechnology methods beyond monoclonal antibodies.

Reuters last month

LZAGY

ROG.SW
+0.90%
Lonza Group's (VTX:LONN) five-year earnings growth trails the favorable shareholder returns

Stock pickers are generally looking for stocks that will outperform the broader market. And the truth is, you can make...

Simply Wall St. last month

LZAGY
30 Most Valuable Drug Companies in 2024

In this article, we will take a look at the 30 most valuable drug companies in 2024. If you want to skip our detailed analysis of the pharmaceutical drugs market, you can go directly to 5 Most Valuable Drug Companies in 2024. The Global Pharmaceutical Drugs Market According to a report by The Business Research […]

Insider Monkey 2 months ago

ABBV

NVO

LLY
Lonza chairman to step down, drugmaker confirms targets, shares soar

(Reuters) -Lonza said on Friday Chairman Albert Baehny will step down in May after six years in the job, in a second senior management reshuffle in recent months as the Swiss contract drug manufacturer grapples with the loss of COVID-related business. Analysts cited relief over outlook confirmation and replacement of a chairman who had overseen guidance cuts and the departure of CEOs. Lonza said it had proposed Jean-Marc Huet, current chairman of the supervisory board of Dutch brewer Heineken, as a new chairman.

Reuters 3 months ago

LZAGY
UPDATE 2-Lonza chairman to step down, drugmaker confirms targets, shares soar

Lonza said on Friday Chairman Albert Baehny will step down in May after six years in the job, in a second senior management reshuffle in recent months as the Swiss contract drug manufacturer grapples with the loss of COVID-related business. The company also reported better-than-expected sales and margins last year and confirmed its 2024 and mid-term margin targets. Lonza said it had proposed Jean-Marc Huet, current chairman of the supervisory board of Dutch brewer Heineken, as a new chairman.

Reuters 3 months ago

LZAGY
A Look At The Fair Value Of Lonza Group AG (VTX:LONN)

Key Insights Lonza Group's estimated fair value is CHF398 based on 2 Stage Free Cash Flow to Equity Current share price...

Simply Wall St. 3 months ago

LZAGY
Lonza Group AG (VTX:LONN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

It is hard to get excited after looking at Lonza Group's (VTX:LONN) recent performance, when its stock has declined 31...

Simply Wall St. 5 months ago

LZAGY
Individual investors who have a significant stake must be disappointed along with institutions after Lonza Group AG's (VTX:LONN) market cap dropped by CHF2.2b

Key Insights Lonza Group's significant individual investors ownership suggests that the key decisions are influenced by...

Simply Wall St. 6 months ago

LZAGY
Investors in Lonza Group (VTX:LONN) have seen respectable returns of 39% over the past five years

It hasn't been the best quarter for Lonza Group AG ( VTX:LONN ) shareholders, since the share price has fallen 21% in...

Simply Wall St. 6 months ago

LZAGY
UPDATE 2-Moderna to cut mRNA drug substance production at Lonza facility

Moderna said on Tuesday it will cut production of mRNA drug substance for its COVID-19 vaccine at Lonza's facility in Switzerland this quarter as part of a plan to align manufacturing of the shots with lower post-pandemic demand. The U.S. company had said last week it was in talks with its partners that fill vials and syringes globally to downsize vaccine production. Such a move will help Moderna adjust to the sharp fall in demand for COVID vaccines as payers cut back orders for the shots, partly following the end of the public health emergency for the disease.

Reuters 7 months ago

TMO

MRNA

SNY
UPDATE 2-Swiss drug ingredient maker Lonza's CEO to leave

Contract drug manufacturer Lonza's Chief Executive, Pierre-Alain Ruffieux, will leave the Swiss company by mutual agreement at the end of the month, it said on Monday. Lonza said its medium-term strategy and outlook would be discussed in detail at its coming capital markets day on Oct. 17 and that Chairman Albert Baehny will take on the CEO responsibilities until the appointment of a permanent successor to Ruffieux. Shares in Lonza, which makes drug ingredients for healthcare and biotech companies, lost 3.3% in premarket trade.

Reuters 7 months ago

LZAGY
ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products

Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces a licensing agreement to develop bispecific ADCs with ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases.

PR Newswire 7 months ago

LZAGF

LZAGY

Performance Overview

Return	LONN.SW	MSCI WORLD
YTD	+48.20%	+5.44%
1-Year	-4.77%	+17.83%
3-Year	-4.33%	+13.20%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Lonza Group AG (LONN.SW)

Lonza Group Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Lonza Group AG's (VTX:LONN) largest shareholders are individual investors with 56% ownership, institutions own 44%

Health Care Roundup: Market Talk

Lonza Taps Siegfried Holding’s Wolfgang Wienand as Next CEO

15 Biggest Swiss Companies

U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies

UPDATE 2-Luxury stocks pressure European equities ahead of Fed verdict

UPDATE 3-Lonza to buy large biologics site from Roche in US for $1.2 bln

Lonza to buy large biologics site from Roche in US for $1.2 billion

Lonza Group's (VTX:LONN) five-year earnings growth trails the favorable shareholder returns

30 Most Valuable Drug Companies in 2024

Lonza chairman to step down, drugmaker confirms targets, shares soar

UPDATE 2-Lonza chairman to step down, drugmaker confirms targets, shares soar

A Look At The Fair Value Of Lonza Group AG (VTX:LONN)

Lonza Group AG (VTX:LONN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Individual investors who have a significant stake must be disappointed along with institutions after Lonza Group AG's (VTX:LONN) market cap dropped by CHF2.2b

Investors in Lonza Group (VTX:LONN) have seen respectable returns of 39% over the past five years

UPDATE 2-Moderna to cut mRNA drug substance production at Lonza facility

UPDATE 2-Swiss drug ingredient maker Lonza's CEO to leave

ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products

Performance Overview